StockData

Monte Rosa Therapeutics vs Kymera Therapeutics

GLUE and KYMR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GLUE and KYMR compare

Kymera Therapeutics is the larger company, worth 13 times as much as Monte Rosa Therapeutics ($10.4B against $774M).

Kymera Therapeutics grew revenue faster over the last twelve months (134% versus −83.9% for Monte Rosa Therapeutics).

Kymera Therapeutics keeps more of each dollar of sales as profit, with a net margin of −342% compared with −561% at Monte Rosa Therapeutics.

Kymera Therapeutics scores higher on the StockData Score (9 against 7 for Monte Rosa Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGLUEKYMR
Size and price
Market cap$774M$10.4B
Share price$9.07$121.52
Change, 1 year−36.8%87.1%
Change, 5 years−55.9%126%
Beta (5Y)2.020.59
Employees150238
StockData Score
Total score79 (better)
Valuation score1 (better)0
Growth score01 (better)
Performance score12 (better)
Health score56 (better)
Dividend score00
Valuation
P/S26.9× (better)101×
P/B1.6× (better)6.4×
FCF yield−4.1%−2.8% (better)
Fair value$6.54$37.15
Margin of safety−38.7% (better)−227%
Growth
Revenue growth (TTM)−83.9%134% (better)
Revenue growth, 5Y average–2.9%
Net income growth (TTM)−767%–
EPS growth (TTM)−707%–
Profitability
Gross margin–0.00%
Operating margin−633%−396% (better)
Net margin−561%−342% (better)
FCF margin−112% (better)−283%
Return on equity−42.7%−27.3% (better)
Return on invested capital–−59.0%
Financial health
Debt / equity0.000.00
Current ratio10.5811.13 (better)
Altman Z-score1.3039.62 (better)
Piotroski F-score5 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions109%114%
Held by insiders11.5%38.3%
Insider net buying, 12 months−$4.1M (better)−$301M
Superinvestors holding1–
Short interest, % of float27.6%16.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.